Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Byler Disease is the result of a homozygous missense (G308V) mutation in the ATP8B1 gene. The
disease is typically manifest in the first year of life on the basis of complications of
cholestasis; common presentations include jaundice, poor growth, bleeding related to vitamin
K deficiency, and/or weak bones related to vitamin D deficiency. Early management of Byler
Disease is directed at nutritional issues which tend to be responsive to medical
intervention, unlike the pruritus/scratching which remains a devastating problem. Progressive
liver disease develops in Byler Disease and can lead to cirrhosis and end-stage liver
disease. This is an open label expanded access protocol of RAVICTI in children with Byler
Disease. The primary hypothesis is that the administration of RAVICTI in these children is
feasible, well tolerated and safe. It is also hypothesized that RAVICTI treatment leads to an
improvement in biochemical markers of liver disease and it may ameliorates or prevents the
development of scratching behavior as a manifestation of pruritus attributed to the liver
disease.